Application of High-Resolution Magnetic Resonance Vessel Wall Imaging in Endovascular Treatment (NCT07497152) | Clinical Trial Compass
CompletedNot Applicable
Application of High-Resolution Magnetic Resonance Vessel Wall Imaging in Endovascular Treatment
China74 participantsStarted 2021-06-01
Plain-language summary
Intracranial atherosclerotic disease (ICAD) is one of the most important causes of ischemic stroke and is also associated with some recurrent stroke. Safety and effective treatment of ICAD is an important precondition to improve the prognosis of patients. The current therapy for middle cerebral artery stenosis was medication and vascular intervention. Traditional assessment methods for intracranial artery, such as magnetic resonance angiography (MRA), computed tomography angiography (CTA) and digital subtraction angiography (DSA), could mainly assess the stenosis degree of the intracranial artery. While, the high-resolution magnetic vessel wall examination has been a pivotal image examination for diagnosing intracranial arterial disease and it provides a unique insight into the atherosclerotic lesions of vessel wall. Therefore, the study aims to explore the association between HRMRI-VWI enhancement for stroke recurrence in ICAS patients treated with MCA angioplasty.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
1）patients aged between 18 and 80 years; 2) ischemic stroke or transient ischemic attack (TIA) involving the target artery within the preceding 90 days those presenting with symptomatic MCA stenosis of 70% or greater, as confirmed by digital subtraction angiography (DSA) based on the WASID criteria; 3) Treating of routine antiplatelet and statin treatment and risk factor management, while would accept cerebral artery angioplasty treatment ; 4) MRS score less than 2 points before angioplasty treatment 5) provided written informed consent.
Exclusion Criteria:
1\) bilateral MCA stenosis or non-atherosclerotic vasculopathies such as moyamoya disease and vasculitis; 2) cardioembolic stroke or other defined etiologies according to the TOAST classification; 3) serious systemic comorbidities (e.g., heart failure, renal insufficiency, or malignancy) that could affect prognosis or procedural safety; 4) contraindications to MRI or contrast agents, including metal implants or severe allergic reactions and poor MRI imaging.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
the occurrence of recurrent ischemic stroke in 15 months
Timeframe: 15 months (±1 month) after angioplasty and stenting